Fact Sheet – API/HPAPI Industry

2012

Global:

The global API market was $101 billion in 2010, expected to grow at rate of 7.9%, reaching

around $136 billion by 2015

Major Markets

North America – 32%, Europe- 31% and Asia – 26%

Major Segments

Merchant API Market - $ 39 billion & API produced and used by companies itself - $ 62 billion

Merchant Market

• Generic API – 48.7%, Branded API – 51.3%

Notable Trends

Increasing influence of API participants, increasing emphasis on High Potency API’s, growth of

generic API market compared to Branded API market

India:

• The Indian bulk drug market during 2010 was $ 8billion, It is expected to grow to $ 20.7

billion by 2015 at increased CAGR of 21 %

Growth Drivers:

Pressures of patent expiry and outsourcing of production by Global Pharma companies

Growing credibility of Indian manufacturers

Increasing penetration of generics in the regulated markets (especially EU and Japan)

Increase in lifestyle related and other diseases

Major Issues: The increase in number of drugs going off patent till 2012, Lack of government

support for bulk drugs industry, the strict environmental laws put up by government, increase in

labor and labor costs associated with increase in production.

HPAPI Market:

Classification – 1) Synthesis route, 2) Customer base

Global: The global HPAPI market is valued at US $8.9 billion in 2011, growing at a CAGR of 8.3% is

projected to reach US $12.18 in 2015

Major Markets: North America, Europe, Asia Pacific

Major Segments: Oncology – 59%, Hormones – 19%, Glaucoma-7 %

India: Indian HPAPI market is valued at Rs.365 crore and is growing at rate of 14.9% reaching

Rs.608 crores in 2015

Major Segments: Prostaglandins, Steroids, Hormones and Oncologicals.

Major Issue: High Capital investment, Complexity in production

Source:

• www.pharmtech.com, www.reuters.com/article-14.02.2012, www.prnewswire.com, www.expresspharmaonline.com-15.12.2011,

www.pharmaintellect.com,www.specchemonline.com, www.gbiresearch.com 2010, Interlink insight Apr – Mar 2012,

www.contractpharma.com/issues - 01.2012

• Interlink Knowledge Cell